Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 4/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL192738 | 1.00 | POLB (0.67) | POLBL3MBTL1MAPTNPSR1HTR2A | |
| Hydrochloric Acid SCHEMBL1401340 | 0.98 | POLB (0.64) | POLBL3MBTL1MAPTNPSR1HTR2A | |
| SCHEMBL4465544 | 0.88 | POLB (0.78) | POLBL3MBTL1MAPTNPSR1HTR2A | |
| SCHEMBL30052469 | 0.88 | POLB (0.58) | POLBL3MBTL1MAPTNPSR1HTR2A | |
| SCHEMBL4896660 | 0.88 | POLB (0.78) | POLBL3MBTL1MAPTNPSR1HTR2A | |
| SCHEMBL23885270 | 0.88 | POLB (0.58) | POLBL3MBTL1MAPTNPSR1HTR2A | |
| SCHEMBL680329 | 0.86 | POLB (0.61) | POLBL3MBTL1MAPTNPSR1HTR2A | |
| SCHEMBL1770841 | 0.86 | POLB (0.56) | POLBL3MBTL1MAPTNPSR1HTR2A | |
| SCHEMBL20509438 | 0.84 | POLB (0.59) | POLBL3MBTL1MAPTNPSR1HTR2A | |
| SCHEMBL30267692 | 0.84 | POLB (0.59) | POLBL3MBTL1MAPTNPSR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642773-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-11-05 | — | — | EP | disclosed |
| WO-2024141444-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-07-04 | — | — | WO | disclosed |
| US-20220289719-A1 | HETEROCYCLIC COMPOUNDS AS MNK INHIBITORS | NANJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2022-09-15 | — | — | US | disclosed |
| EP-3989966-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-114126613-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289719-A1 | HETEROCYCLIC COMPOUNDS AS MNK INHIBITORS | NIM1K, MAP3K1, MAPKAPK2 | POLB 1948/4885L3MBTL1 3380/4885MAPT 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.